Key Takeaways
- Absci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves.
- Schrödinger’s rally has the most business behind it, and Absci’s rally is mostly about investors’ appetite for risk.
- In the second quarter of 2026, Absci had $0.3 million of revenue and burned $27.6 million of free cash flow. Management says its cash lasts into the second half of 2028.
- Absci’s third-quarter report on Nov. 12 is the next real test.
Absci (ABSI) shares jumped 12% today. The company’s only news was an 8 a.m. note saying it will attend some upcoming investor conferences.
It had plenty of company. Schrödinger (SDGR) rose 11% and Recursion (RXRX) gained 9%, while Twist Bioscience, Tempus AI and 10x Genomics rose 8% to 10%. The Nasdaq 100 and the small-cap Russell 2000 each rose 1%, so this looks like a risk-on day lifting the whole group.
Same rally, very different businesses
Schrödinger has real revenue to price: $255.9 million in 2025, up 23% from 2024. And even after a big run off February’s lows, its forward price/sales multiple is close to its five-year average.
Today’s jump takes it closer to 9x. That’s a bit above its average, but nowhere near the nearly 27x it hit in 2021.
Recursion is further from paying its own way. Over the trailing 12 months it had $54.9 million of revenue and a $518.9 million net loss. It did raise $200 million at $3.25 a share on Oct. 15, so the cash is there for now.
TIKR tracks 11 analysts on Absci. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Absci, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Absci’s Analyst Ratings
Absci runs on sentiment
Absci is the furthest of the three from its fundamentals. It brought in $0.3 million of revenue in the second quarter of 2026. Even before today’s jump, it was worth roughly eight times its cash and short-term investments. That cash rose sharply in the June quarter after a $100 million stock offering, which included a $40 million strategic investment from Eli Lilly…
…and Absci has burned $26 million to $29 million of free cash flow in each of the past four quarters:
Management says its cash should fund operations into the second half of 2028, so there’s no funding crunch coming soon. The valuation rests on ABS-201, which posted positive interim Phase 1 data in the HEADLINE trial this year.
Nov. 12 is the real test
My take: Schrödinger’s rally has the most business behind it. Absci’s rally is a bet on ABS-201 riding a risk-on day. A stock that jumps 12% on no news can give it back just as fast when the mood turns.
The next real news comes soon. Recursion hosts a webinar on updated REC-4881 data on Nov. 3. Schrödinger reports after the close on Nov. 4, and Absci reports before the open on Nov. 12.
So what is Absci stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Absci could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
